Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Genscript Biotech Corporation

GenScript Antibody Services

GenScript Discovery Biology Services

GenScript Protein Services

GenScript Peptide Services

GenScript Catalog Products

GenScript Gene Services

GenScript Synthetic Biology Services

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has over 5,000 employees globally, 33% holding master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 100 patents and over 270 patent applications. As of June 2022, GenScript's products and services have been cited by 74,700 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

GenScript

📩 GenScript would like to invite you to the 𝙂𝙚𝙣𝙎𝙘𝙧𝙞𝙥𝙩 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙂𝙡𝙤𝙗𝙖𝙡 𝙁𝙤𝙧𝙪𝙢 2024 at the Grand Hyatt in San Francisco on January 10, 2024.
 
Join us in uniting global thought leaders dedicated to advancing cures that will impact the lives of countless patients. It is an exclusive event where insights converge, focusing on recent developments, technological breakthroughs, commercialization challenges, and regulatory trends.
 
We would be honored to have you as our guest 👏 ! Secure your complimentary pass today using code "GS2024" on our event registration page: https://lnkd.in/eB94K5fk.
 
Your active engagement is critical in shaping the future of cell and gene therapy. Let's make a difference together 🤝 !

#biotechnology #lifesciences #genetherapy #celltherapy #biotechindustry #GSforum2024 

We are thrilled to announce GenScript has been named a BioSpace 2024 Best Place to Work!

We are grateful for our incredible team members who make our workplace truly exceptional. 

Cheers to the shared passion and dedication that sets us apart!

#bestplacetowork #teamwork


#researchadvance The microbiome, consisting of diverse microorganism communities including viruses, bacteria, fungi and eukaryotes colonizing human body surfaces, has recently been identified as a contributor to inter-individual variation, through its person-specific signatures. 

A recent review explores recent advances in the application of microbiome data in precision medicine across a growing number of human diseases. 

In this paper, researchers discuss the challenges, limitations and prospects of analysing microbiome data for personalized patient care. Eran Elinav Suhaib K. Abdeen

Read now: https://lnkd.in/e5mJK5wP

#microbiome #microorganism #humandiseases #precisionmedicine #patientcare #biotech 

Looking for high-quality Anti-DYKDDDDK affinity resins with great binding capacity and purity? 

Try GenScript's anti-DYKDDDDK G1 affinity resin (L00432), trusted by real users for top-notch purification in different expression systems! Explore user reviews and order now for speedy delivery.

Check out more details: https://lnkd.in/eiZEs4Mr

#catalogproducts #topnotch #highquality #offthechart #affinityresin #GSproducts 

Scientists from the University of Virginia School of Medicine have targeted lipid oxidation in the chronic liver disease, Non-Alcoholic Fatty Liver Disease (NAFLD), with an AAV8 delivered antibody fragment (scFv-E06). 

Learn how this approach is performing preclinically, providing a new opportunity to manage a disease with a global prevalence of over 30% and no FDA approved drugs: https://lnkd.in/eKQYbQfS

#liverdisease #antibodies #genetherapy #geneengineering #geneediting

COM:GENSCRIPT